Posted by: admin on: June 29, 2011
Folate-Boosted Oral Contraceptive is intended to reduce the risk for rare neural tube defects in a pregnancy conceived during its use or shortly thereafter The US Food and Drug Administration (FDA) has approved an oral contraceptive Safyral in which 451 μg levomefolate calcium has been added to each tablet of a 21/7 drospirenone 3 mg/estradiol […]
Posted by: admin on: May 6, 2011
All drugs are monitored rigidly, even after having been approved by FDA, for reported adverse effects and drug interactions. It is duty of every practitioner to report – both to the manufacturer and FDA – any unreported adverse effect (maybe in one patient) for rational monitoring and necessary action. Team@CMHF
Posted by: admin on: April 27, 2011
Medscape recently published a debate posing the below mentioned questions to Dr. Charles Argoff, a neurologist specializing in pain and Dr. Jonathan Kay, a rheumatologist. – What is fibromyalgia, aside from being a major frustration to patients and clinicians? – And what causes it? Dr Argoff said that fibromyalgia is itself a distinct condition associated […]